Advertisement

Topics

Treatment of Hepatorenal Syndrome With Terlipressin Plus Albumin vs Albumin

2014-07-24 14:25:43 | BioPortfolio

Summary

Hepatorenal syndrome is a common complication of cirrhotic patients. The prognosis of patients with HRS is very poor. It have been demonstrated that vasoconstrictors agents (Terlipressin) plus albumin are effective in the reversal of the treatment. However, previous studies are pilot studies and they are not able to give information about an improvement in survival. This comparative randomized study was delineated to test the efficacy of terlipressin on survival.

Description

Phase 3

Study Design

Allocation: Randomized, Control: Active Control, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Cirrhosis

Intervention

terlipressin

Location

Hospital Clinic
Barcelona
Spain
08036

Status

Suspended

Source

Hospital Clinic of Barcelona

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-24T14:25:43-0400

Clinical Trials [358 Associated Clinical Trials listed on BioPortfolio]

Continuous Versus Bolus Infusion of Terlipressin for Portal Hypertension Related Bleeding in Liver Cirrhosis

Terlipressin is the mainstay drug for the treatment of acute variceal bleeding in liver cirrhosis. According to the drug instructions, intravenous bolus infusion is the standard approach o...

Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome

From 1999, several studies have showed that the use of vasoconstrictors in association with albumin are effective in the treatment of hepatorenal syndrome (HRS). The rationale of the use o...

Terlipressin in Cirrhotic Patients With Recidivation Ascites Treated With Paracentesis and Albumin

Ascites is a common complication of cirrhosis. Sodium restriction and diuretics are the first step treatment. Refractory ascites (not responding to first step treatment) is treated with re...

Renal and Cardiovascular Effects of Terlipressin in Patients With Cirrhosis and Ascites

The purpose of this study is to investigate the effect of terlipressin on myocardial perfusion and renal function. Hypothesis: Significant improvement of renal function reflected by: glom...

Terlipressin in Septic Shock in Cirrhosis

Septic shock is a frequent and severe complication in cirrhosis. Current mortality rate ranges between 50 and 80% of cases. Refractory shock, hepatorenal failure and variceal bleeding are ...

PubMed Articles [466 Associated PubMed Articles listed on BioPortfolio]

Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure.

Hepatorenal syndrome (HRS) carries a high short-term mortality in patients with cirrhosis and ACLF. Terlipressin and noradrenaline are routinely used in cirrhosis with HRS and have been found to be eq...

"Letter To Editor: Terlipressin is Superior to Noradrenaline in the Management of Acute Kidney Injury in Acute On Chronic Liver Failure".

The article by Arora et al. (2018) compared use of two vasoconstrictors terlipressin and noradrenaline in the management of acute kidney injury in ACLF patient. Numerous other trials have shown no di...

Severe reversible penile ischaemia after terlipressin treatment of hepatorenal syndrome.

This case report presents a 70-year-old man with alcoholic liver cirrhosis, who was hospitalised due to pulmonary oedema, and who developed acute renal injury. Though the criteria were not fulfilled, ...

Letter to editor: Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute-on-chronic liver failure.

We read with interest the paper by Arora et al comparing terlipressin with noradrenaline in the management of acute kidney injury (AKI) in patients with acute-on-chronic liver failure (ACLF). The aut...

The Conundrum of Cryptogenic Cirrhosis: Adverse Outcomes without Treatment Options.

Although patients with cryptogenic cirrhosis have been historically considered to have "burnt out" nonalcoholic steatohepatitis (NASH), some controversy remains. The aim was to compare outcomes of pat...

Medical and Biotech [MESH] Definitions

Experimentally induced chronic injuries to the parenchymal cells in the liver to achieve a model for LIVER CIRRHOSIS.

FIBROSIS of the hepatic parenchyma due to obstruction of BILE flow (CHOLESTASIS) in the intrahepatic or extrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC; BILE DUCTS, EXTRAHEPATIC). Primary biliary cirrhosis involves the destruction of small intra-hepatic bile ducts and bile secretion. Secondary biliary cirrhosis is produced by prolonged obstruction of large intrahepatic or extrahepatic bile ducts from a variety of causes.

FIBROSIS of the hepatic parenchyma due to chronic excess ALCOHOL DRINKING.

Abnormal increase of resistance to blood flow within the hepatic PORTAL SYSTEM, frequently seen in LIVER CIRRHOSIS and conditions with obstruction of the PORTAL VEIN.

Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.

More From BioPortfolio on "Treatment of Hepatorenal Syndrome With Terlipressin Plus Albumin vs Albumin"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...


Searches Linking to this Trial